Trial Profile
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Sep 2022
Price :
$35
*
At a glance
- Drugs Silmitasertib (Primary) ; Cisplatin; Gemcitabine
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Senhwa Biosciences
- 24 Sep 2022 Results published in the Hepatology
- 18 Mar 2021 Planned End Date changed from 1 Mar 2021 to 31 May 2021.
- 17 Jan 2021 Interim Results assessing safety and efficacy of silmitasertib in combination with gemcitabine plus cisplatin in patients with unresectable cholangiocarcinoma, presented at the 2021 Gastrointestinal Cancers Symposium